Crescita Therapeutics (TSE:CTX) Stock Price Up 5.4% – Should You Buy?

Crescita Therapeutics Inc. (TSE:CTX)’s stock price was up 5.4% during mid-day trading on Monday . The stock traded as high as C$0.60 and last traded at C$0.59. Approximately 20,875 shares were traded during mid-day trading, an increase of 102% from the average daily volume of 10,325 shares. The stock had previously closed at C$0.56.

Crescita Therapeutics Trading Down 1.7 %

The business’s 50-day moving average price is C$0.56 and its two-hundred day moving average price is C$0.58. The company has a debt-to-equity ratio of 5.77, a current ratio of 2.70 and a quick ratio of 2.29. The firm has a market cap of C$10.68 million, a price-to-earnings ratio of -3.94 and a beta of 1.69.

Insider Activity

In other Crescita Therapeutics news, Director Jose Darocha bought 86,000 shares of the business’s stock in a transaction on Friday, December 27th. The shares were purchased at an average price of C$0.60 per share, with a total value of C$51,436.60. Insiders own 10.87% of the company’s stock.

Crescita Therapeutics Company Profile

Crescita Therapeutics Inc, a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp.